GIGA-kids -- Genomics of IgA-related diseases in kids

Principal Investigator: Raoul  Nelson
Keywords: Nephropathy , IgA , Henoch-Schönlein Department: Pediatric Administration
IRB Number: 00074302 Co Investigator:  
Specialty: Pediatrics, General
Sub Specialties:
Recruitment Status: Recruiting

Contact Information

JoAnn Narus
joann.narus@hsc.utah.edu
801-585-7497

Brief Summary

Aim 1: To recruit a well powered cohort of pediatric patients with IgAN and HSP (with or without nephritis) for the purpose of genetic and biomarker studies.

1a) Collect DNA and serum from 500 children with biopsy-diagnosed IgAN

1b) Collect DNA and serum from 500 children with a clinical diagnosis of HSP with or without nephritis

1c) Recruit 200 healthy age- and ethnicity-matched controls for the purpose of biomarker studies.

 

Aim 2: To perform genetic and biomarker studies in this patient cohort:

2a) Test for validation of the existing adult GWAS loci in pediatric population.

2b) Test for validation of serum Gd-IgA1 level as a biomarker for IgAN and HSPN in children.

2c) Improve the representation of children in subsequent genetic and biomarker discovery studies.

 

Inclusion Criteria

IgA nephropathy: all prevalent patients with biopsy-documented diagnosis using standard

histopathologic criteria (typical light microscopic features with dominant or co-dominant staining for

IgA on immunofluorescence microscopy; electron microscopy is not required). All ages, all

ethnicities, and all stages of CKD are eligible.

HSP with and without nephritis: all prevalent patients with history of or presence of purpuric skin

lesions (regardless of renal involvement) suspected to have a clinical diagnosis of HSP (with or

without nephritis) are eligible to participate in the study. There is no requirement for a renal biopsy.

All ages, all ethnicities, and all stages of CKD are eligible.

Healthy controls: age- and ethnicity-matched children who are unrelated to the cases and have no

history of kidney disease or skin purpura.

Exclusion Criteria

• Pre-existing diagnosis of autoimmune disease, liver disease, active HBV, HCV, or HIV infections.